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Abstract: Joint pain causes significant morbidity in osteoarthritis (OA). The aetiology of joint pain
in OA is not well understood. The synovial membrane as an innervated joint structure represents a
potential source of peripheral pain in OA. Here we analyse, using a hypothesis-free next generation
RNA sequencing, the differences in protein-coding and non-coding transcriptomes in knee synovial
tissues from OA patients with high knee pain (n = 5) compared with OA patients with low knee pain
(n = 5), as evaluated by visual analogue scale (VAS). We conduct Gene Ontology and pathway analyses
on differentially expressed mRNA genes. We identify new protein-coding, long non-coding RNA and
microRNA candidates that can be associated with OA joint pain. Top enriched genes in painful OA
knees encode neuronal proteins that are known to promote neuronal survival under cellular stress
or participate in calcium-dependent synaptic exocytosis and modulation of GABA(γ-aminobutyric
acid)ergic activity. Our study uncovers transcriptome changes associated with pain in synovial
microenvironment of OA knees. This sets a firm ground for future mechanistic studies and drug
discovery to alleviate joint pain in OA.
Keywords: pain; osteoarthritis; knee; synovium; RNA-seq
1. Introduction
Primary knee osteoarthritis (OA) is the most common joint disorder, affecting more than 10% of
the Western European population aged 60 years or older [1]. Joint pain and functional disability
decrease quality of life in OA patients [2]. OA affects hands, feet, knees, hips and spine [3] with
structural damage in the articular cartilage, subchondral bone, ligaments, tendons, menisci, muscles,
synovium and nerve tissues [4]. The ethiopathogenesis of joint pain in OA is not well understood [5]
and the therapeutic strategies to relieve OA pain are therefore limited. The correlation between the
severity of pain and the degree of radiographic changes in OA knees is poor [6,7].
A number of studies substantiate the role of the central nervous system in the ethiopathogenesis
of chronic pain in OA [8,9], nevertheless the sources of peripheral nociception are increasingly
explored [6,10]. Peripheral pain can originate in any of the innervated joint structures, including
the synovium [5]. Synovial inflammation in OA causes joint pain [11]. Inflammation decreases
the activation threshold of local afferent nerve fibers in response to mechanical stimuli resulting in
peripheral sensitisation. Additionally, interactions between a damaged joint and the sensory nervous
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system cause pain [11]. Most likely, there are two interconnected mechanisms with reverse causality:
Joint damage causes synovial inflammation, whereas neurogenic inflammation contributes to joint
damage, creating a positive feedback loop [12].
Genes involved in pain pathways in the nervous system are also expressed in non-neuronal cells
of the joint [13]. Epidemiology studies identified a panel of candidate genes and functional genetic
variants associated with OA pain [14]. To date, no hypothesis-free study with a genome-wide approach
has been conducted to interrogate the molecular basis of OA pain.
Here we analyse by RNA sequencing the transcriptomes of knee synovial tissues from OA patients
with high and low intensity knee pain as assessed by visual analogue scale (VAS). We uncover the
molecular complexity of OA joint pain and reveal novel candidate genes associated with knee OA pain.
2. Materials and Methods
2.1. Patient Information
OA patients (Table 1) were enrolled in the study at the Uniklinik Balgrist, Zurich, Switzerland.
Pain was assessed a day before surgery by a clinical investigator using a 10-point VAS. Patients with
low (VAS scores: 0–3) or high (VAS 7–10) pain were enrolled. The indication for surgery in patients
with low pain were a relevant deformity of the axis, mainly valgus, and/or loss of bone stock with
a symptomatic instability and risk to fall. The Local Ethical Committee (KEK-ZH-Nr. 2013-0210)
approved the study. All patients gave written informed consent. All experiments were performed in
accordance with relevant guidelines and regulations.
2.2. Sample Collection and Total RNA Extraction
The standardized surgical excision (excision of the capsule with synovia in the recessus
suprapatellaris) was performed. The biopsies (two per patient with the size of approximately 2 cm2)
were fresh frozen (dry ice) and RNA was extracted randomly from one biopsy using TRIzol® Reagent
(Thermo Fisher Scientific, Waltham, MA, USA). RNA was analysed by Qubit® 1.0 Fluorometer (Thermo
Fisher Scientific) and Agilent 2200 TapeStation (Agilent Technologies, Santa Clara, CA, USA); RNA
with RIN (RNA Integrity Number) values 8.3–9.1 was used for sequencing.
2.3. Next Generation Sequencing
Libraries for mRNA/long noncoding RNA (lncRNA) and small RNA sequencing were prepared
using the Illumina (San Diego, CA, USA) TruSeq® Stranded total RNA Sample Preparation Kit and
the NEBNext® Small RNA Library Prep Set for Illumina®, respectively. Libraries were quantified
and quality checked using quantitative polymerase chain reaction (qPCR) (Roche, Basel, Switzerland)
with Illumina adapter specific primers and Agilent 2200 TapeStation, respectively. Diluted indexed
mRNA-seq (10 nM) and small RNA-seq (1 nM) libraries were pooled, used for cluster generation
(Illumina TruSeq SR Cluster Kit v4-cBot-HS) and sequenced (Illumina HiSeq 2500, Illumina TruSeq
SBS Kit v4-HS reagents, single read approach (1 × 125 bp) with 20–30 million reads per sample for
mRNA/lncRNA, 10–20 million reads for miRNA).
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Table 1. Information about the patients enrolled into study.
Patient
No. Sex Age Nationality
Smoking
Status Drug Therapy
Classes of
Medicaments
Recommended
Procedure for
Surgery
Degree of
Radiographic Changes
in the Knee 3
Current
Laboratory Data:
CRP 4/BSG 5
Earlier
Surgery
Procedures
BMI 6 VAS 7 Pain
012 F 1 76 Swiss non
Pantozol, Pravastatin,
Torasemid, Triatec 1, 5, 3, 4 TKA
2 4 8.3/18 Meniscus 27.5 8 high
013 F 64 Italian non Co-Aprovel 5 TKA 4 8.5/50 non 31.8 3 low
014 F 74 Swiss non non non TKA 4 1.2/20 Meniscus 23.4 0 low
015 F 75 Swiss non Lithium 6 TKA 4 0.5/12 non 23.7 1 low
016 F 62 Swiss non Metoprolol, Sirdalud,Femeston, Pantozol 2, 10, 7, 1 TKA 3 4.6/14 non 23.2 9 high
017 F 70 German non Fludex 3 TKA 4 -/- non 43.7 8 high
018 F 78 Swiss non
Atenolol, Co-Epril,
Madopar, Metformin,
Simcora, Tiatral,
Zanidip, Tramadol
2, 4, 6, 8, 5, 10 TKA 4 7.7/22 non 35.5 7 high
019 F 67 Swiss non Tilur, Zolpidem 10, 6 TKA 4 1.1/7 non 25.4 8 high
021 F 65 Swiss non Aspirin, Surmontil 10, 6 TKA 4 5.4/17 Arthroscopy 32 0–3.5 8 low
022 F 77 Italian non
Aspirin, Calcimagon,
Magnesium, Pantozol,
Pemzek
10, 9, 1, 4 TKA 4 9.2/29 non 34.2 2 low
Classes of medicaments: (1) proton pump inhibitors, (2) β-blockers, (3) diuretics, (4) Angiotensin-converting enzyme (ACE) inhibitors, (5) drugs decreasing cholesterol blood level,
(6) medicaments against psychiatric disorders, (7) hormonal replacement therapy, (8) diabetes, (9) drugs against osteoporosis, (10) pain killers; β-blockers, diuretics, ACE inhibitors and
ZANIDIP (unclassified) are all against high blood pressure or heart disease. 1 F: female, 2 TKA: Total Knee Arthroplasty, 3 according to Kellgren and Lawrence system grade [15], 4 CRP:
C–Reactive Protein, 5 BSG: Blood Sedimentation Rate, 6 BMI: Body Mass Index, 7 VAS: Visual Analog Scale, 8 patient with VAS at rest 0 and under loading with 3.5.
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2.4. Data Analysis
After quality control (FastQC, Babraham Bioinformatics, https://www.bioinformatics.babraham.
ac.uk/) we quantified transcript expressions using the RSEM package (version 1.2.18) [16].
Transcript references were built using the Ensembl version 75 annotations of the GRCh37.p13 human
genome assembly. The expression level for each gene was obtained by the aggregation of counts from
all gene isoforms. Genes with less than 10 counts in≥50% of samples for each condition were excluded
from the analysis. Small RNA reads were processed using the ncPRO-seq [17] and annotated using
miRbase version 20 [18], RepeatMasker and Rfam [19].
Differentially expressed genes were identified using the R/bioconductor package edgeR
(v3.14.0) [20]. The Benjamini-Hochberg procedure [21] was used to adjust p values and genes
with an adjusted p value ≤ 0.11 were considered differentially expressed. Gene ontology (GO)
enrichment analysis was conducted using the Overrepresentation Test from PANTHER web portal
(release 2015043074) [22] on biological process ontologies, using Fisher’s exact test option and all genes
in the database as a background. Redundant GO terms were removed using the REVIGO portal [23].
Pathway analysis was performed using the gene set enrichment analysis tool using MSigDB curated
gene sets (C2, release 5) [24,25]. GO terms and pathways with adjusted p value ≤0.05 were considered
enriched. Small RNAs with an absolute log2 fold change ≥1 and p value ≤0.05 were defined as
differentially expressed.
Deconvolution of synovial tissue into immune cell types was evaluated using an mRNA
machine learning approach of CIBERSORT [26], running the relative and absolute modes and using
500 permutations. Input matrix contained fragments per kilobase million (FPKM) for all expressed
genes. CIBERSORT uses the reference dataset LM22 that consist of 22 distinct immune cell types and was
constructed from gene expression profiles of those cell types measured on the Affymetrix U133A/Plus2
(Santa Clara, CA, United States and Illumina Expression BeadChip (HumanHT-12 v4) platforms.
The raw and processed RNA-seq data have been deposited under Gene Expression Omnibus
(GEO) accession number GSE99662.
3. Results
3.1. Protein-Coding Transcriptome and Gene Enrichment Analysis
We identified 32 genes that were differentially expressed in the synovium of OA patients with
low and high pain (Table 2). Among these 32 mRNAs, 30 mRNAs were up-regulated in OA synovium
from patients with high pain compared with patients experiencing low pain. The top up-regulated
genes were the Stress Responsive DNAJB4 Interacting Membrane Protein (SDIM1), Carboxypeptidase
E (CPE) and Otoferlin (OTOF). Ankyrin Repeat Domain 20 Family Member A4 (ANKRD20A4) and
pentraxin 3 (PTX3) were the only down-regulated genes in OA synovium from patients experiencing
high pain (Table 2).
To identify biological processes enriched in the synovium of OA patients with high knee
pain, we performed the GO enrichment analysis and gene set enrichment analysis (GSEA) on
the 32 differentially expressed genes. Six GO sets were enriched in patients with high pain
(Table 3). Only two of the enriched GO term have a relative small size (<200 genes), Peripheral
nervous system development (GO:0007422) and Second-messenger-mediated signalling (GO:00019932).
The characteristics of the 18 genes that were enriched in these GO terms are described in the Table 4
and Table S1. We identified two enriched Reactome pathways, specifically Nerve growth factor (NGF)
signalling via Tropomyosin receptor kinase A (TRKA) from the plasma membrane and Signalling by
NGF (Table 5). These two pathways were redundant with four significantly enriched genes including
adenylate cyclase 3 (ADCY3), Src homology 2 domain containing (SHC) transforming protein 2 (SHC2),
neurotrophic receptor tyrosine kinase 2 (NTRK2) and dual specificity phosphatase 4 (DUSP4).
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Table 2. List of genes and long noncoding RNAs differentially expressed in synovial tissue of patients with contrast pain phenotypes.
No. Gene ID Gene Name Description Type log2 Fold Change p Value Adjusted p Value
1 ENSG00000256391 SDIM1 stress responsive DNAJB4 interacting membrane protein 1 protein_coding 2.913 2.83 × 10−10 4.66 × 10−6
2 ENSG00000115155 OTOF otoferlin protein_coding 3.42 7.70 × 10−8 0.000634
3 ENSG00000109472 CPE carboxypeptidase E protein_coding 1.107 2.13 × 10−7 0.001172
4 ENSG00000138944 KIAA1644 KIAA1644 protein_coding 1.184 1.93 × 10−6 0.007935
5 ENSG00000158258 CLSTN2 calsyntenin 2 protein_coding 1.214 6.48 × 10−6 0.01909
6 ENSG00000131471 AOC3 amine oxidase, copper containing 3 protein_coding 1.243 8.55 × 10−6 0.01909
7 ENSG00000141068 KSR1 kinase suppressor of ras 1 protein_coding 0.8648 9.15 × 10−6 0.01909
8 ENSG00000108551 RASD1 RAS, dexamethasone-induced 1 protein_coding 1.605 1.04 × 10−5 0.01909
9 ENSG00000042062 FAM65C family with sequence similarity 65, member C protein_coding 1.655 1.04 × 10−5 0.01909
10 ENSG00000138031 ADCY3 adenylate cyclase 3 protein_coding 0.8997 1.29 × 10−5 0.02012
11 ENSG00000120875 DUSP4 dual specificity phosphatase 4 protein_coding 1.297 1.42 × 10−5 0.02012
12 ENSG00000113448 PDE4D phosphodiesterase 4D, cAMP-specific protein_coding 1.083 1.47 × 10−5 0.02012
13 ENSG00000172014 ANKRD20A4 ankyrin repeat domain 20 family, member A4 protein_coding −2.373 1.70 × 10−5 0.02151
14 ENSG00000221866 PLXNA4 plexin A4 protein_coding 1.232 2.43 × 10−5 0.02859
15 ENSG00000213494 CCL14 chemokine (C-C motif) ligand 14 protein_coding 1.212 3.10 × 10−5 0.03001
16 ENSG00000198947 DMD dystrophin protein_coding 0.9328 3.29 × 10−5 0.03006
17 ENSG00000166106 ADAMTS15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 protein_coding 1.038 4.98 × 10−5 0.0432
18 ENSG00000135744 AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) protein_coding 1.732 6.87 × 10−5 0.05489
19 ENSG00000129946 SHC2 SHC (Src homology 2 domain containing) transforming protein 2 protein_coding 1.574 7.00 × 10−5 0.05489
20 ENSG00000104332 SFRP1 secreted frizzled-related protein 1 protein_coding 0.953 7.41 × 10−5 0.05551
21 ENSG00000137285 TUBB2B tubulin, beta 2B class IIb protein_coding 1.592 8.44 × 10−5 0.06047
22 ENSG00000163431 LMOD1 leiomodin 1 (smooth muscle) protein_coding 1.02 0.000143 0.09593
23 ENSG00000103196 CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 protein_coding 1.631 0.000146 0.09593
24 ENSG00000065320 NTN1 netrin 1 protein_coding 1.48 0.000154 0.09774
25 ENSG00000163661 PTX3 pentraxin 3, long protein_coding −2.075 0.000174 0.1009
26 ENSG00000144229 THSD7B thrombospondin, type I, domain containing 7B protein_coding 1.88 0.000181 0.1009
27 ENSG00000165507 C10orf10 chromosome 10 open reading frame 10 protein_coding 1.002 0.000185 0.1009
28 ENSG00000017427 IGF1 insulin-like growth factor 1 (somatomedin C) protein_coding 1.159 0.000195 0.1009
29 ENSG00000148053 NTRK2 neurotrophic tyrosine kinase, receptor, type 2 protein_coding 1.176 0.000195 0.1009
30 ENSG00000162878 PKDCC protein kinase domain containing, cytoplasmic protein_coding 0.9649 0.000196 0.1009
31 ENSG00000171819 ANGPTL7 angiopoietin-like 7 protein_coding 1.825 0.000204 0.1017
32 ENSG00000111879 FAM184A family with sequence similarity 184, member A protein_coding 1.44 0.000219 0.1061
33 ENSG00000266037 RN7SL3 RNA, 7SL, cytoplasmic 3 other −4.882 2.72 × 10−5 0.02982
34 ENSG00000230847 RP11-195E2.1 pseudogene −2.975 2.90 × 10−5 0.02985
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Table 3. Enriched Gene Ontologies terms for the 32 genes differentially expressed in synovial tissue of patients with contrast pain phenotypes.
Gene Ontology (GO) Term Term ID Ontology Gene Set Size Differentially ExpressedGenes in Set
Expected
Proportion
Fold
Enrichment Direction
Adjusted
p Value
Peripheral nervous system development GO:0007422 BP 1 74 4 0.11 >5 Up-regulation 3.62 × 10−2
Second-messenger-mediated signalling GO:0019932 BP 149 5 0.22 >5 Up-regulation 2.13 × 10−2
Regulation of MAPK cascade GO:0043408 BP 771 9 1.15 >5 Up-regulation 9.79 × 10−3
Regulation of protein phosphorylation GO:0001932 BP 1330 11 1.98 >5 Up-regulation 1.44 × 10−2
Regulation of phosphorylation GO:0042325 BP 1419 11 2.11 >5 Up-regulation 2.70 × 10−2
Anatomical structure morphogenesis GO:0009653 BP 2341 14 3.49 4.02 Up-regulation 1.64 × 10−2
1 BP-biological processes.
Table 4. Gene Ontologies (GO) in the category of biological process and 18 enriched genes among 32 differentially expressed in synovial tissue of patients with
contrast pain phenotypes. All enriched genes are up regulated in painful knee (Table 2).
Gene Ontology
SD
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C
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f1
0
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N
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2
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C
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18
4A
Peripheral nervous system development x x x x
Second-messenger-mediated signaling x x x x x
Regulation of MAPK cascade x x x x x x x x x
Regulation of protein phosphorylation x x x x x x x x x x x
Regulation of phosphorylation x x x x x x x x x x x
Anatomical structure morphogenesis x x x x x x x x x x x x x x
Unclassified x x x x
Table 5. Results from the Gene Set Enrichment Analysis (GSEA) based on Reactome datasets.
Gene Set Reactome ID Description Genes in Overlap p Value Adjusted p Value
NGF signaling via TRKA from
the plasma membrane R-HSA-187037
Genes involved in NGF signaling via
TRKA from the plasma membrane 4 2.23 × 10
−6 1.92 × 10−3
Signaling by NGF R-HSA-166520 Genes involved in Signaling by NGF 4 1.38 × 10−5 5.92 × 10−3
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3.2. Noncoding Transcriptome
Two lncRNAs (RN7SL3 and RP11-195E2.1) and thirty-five miRNAs were identified as differentially
expressed in the synovium of OA patients with contrast pain phenotypes (Tables 1 and 6). Twenty-one
miRNAs were down-and fourteen were up-regulated in patients with high compared with low knee
pain, but these differences were not significant when correcting for false discovery rate (FDR) (Table 6).
Table 6. List of small RNAs significantly differentially expressed in synovial tissue of patients with
contrast pain phenotypes; raw p value < 0.05 and absolute log2 fold change (logFC) ≥ 1; FDR: false
discovery rate).
No. Small RNA ID logFC p Value FDR
1 hsa-miR-146a-3p −3.0904 0.0021 0.9161
2 hsa-miR-3690 −2.0150 0.0061 0.9161
3 hsa-mir-6087 −1.0671 0.0094 0.9161
4 hsa-mir-3690-2 −1.9481 0.0105 0.9161
5 hsa-mir-3690-1 −1.9481 0.0105 0.9161
6 hsa-miR-483-3p 1.3561 0.0108 0.9161
7 hsa-miR-27a-5p −1.3216 0.0110 0.9161
8 hsa-mir-579 1.1104 0.0136 0.9161
9 hsa-mir-133a-2 1.2010 0.0176 0.9161
10 hsa-miR-219a-1-3p −1.4028 0.0188 0.9161
11 hsa-miR-133a-5p 1.4021 0.0191 0.9161
12 hsa-miR-493-3p −1.3788 0.0195 0.9161
13 hsa-mir-133a-1 1.2001 0.0200 0.9161
14 hsa-miR-1245a −1.3254 0.0214 0.9161
15 hsa-miR-23a-5p −1.3435 0.0217 0.9161
16 hsa-miR-133a-3p 1.1719 0.0219 0.9161
17 hsa-mir-7704 −1.0055 0.0250 0.9161
18 hsa-miR-550a-3p 1.2909 0.0272 0.9161
19 hsa-miR-4508 −1.5594 0.0285 0.9161
20 hsa-mir-4508 −1.5594 0.0285 0.9161
21 hsa-miR-579-5p 1.2289 0.0339 0.9161
22 hsa-miR-215-5p 1.1979 0.0363 0.9161
23 hsa-miR-514a-3p 1.4606 0.0374 0.9161
24 hsa-mir-215 1.1756 0.0390 0.9161
25 hsa-mir-6818 −1.2591 0.0400 0.9161
26 hsa-mir-514a-3 1.4891 0.0413 0.9161
27 hsa-mir-514a-1 1.4891 0.0413 0.9161
28 hsa-mir-514a-2 1.4891 0.0413 0.9161
29 hsa-mir-3651 −1.6337 0.0423 0.9161
30 hsa-mir-1294 −1.0721 0.0426 0.9161
31 hsa-mir-135b −1.6181 0.0428 0.9161
32 hsa-miR-135b-5p −1.6110 0.0433 0.9161
33 SNORA3 −1.1678 0.0450 0.9161
34 hsa-miR-1294 −1.0974 0.0472 0.9161
35 hsa-mir-7854 −1.2553 0.0473 0.9161
3.3. Deconvolution Analysis of Harvested Synovial Tissue
There were no major differences in immune cell composition (Kruskal-Wallis test, adjusted p value
≤ 0.05) nor in the absolute content of immune cells (Kruskal-Wallis test, p = 0.17) in the synovium
between patients (Figure 1A). The expression level of CD45 (PTPRC), a leukocyte marker (Figure 1B)
did not differ between synovial tissues from patients with high and low pain (adjusted p = 0.78).
In addition, fibroblast markers CLU, COL1A2, COL3A1, identifying for different subpopulations of
synovial fibroblasts [27] were expressed at high levels in synovial tissues (log2 FPKM > 9) and their
expression did not differ between patients with contrast pain phenotypes (Figure 1B).
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Figure 1. Deconvolution analysis of the cell composition in synovial tissue extracts based on
RNA-sequencing data. (A) Fraction of leukocyte type content as inferred by CIBERSORT. (B) Expression
levels of fibroblast (CLU, COL1A2, COL3A1) and leukocyte (PTPRC) marker genes. FPKM, Fragments
Per Kilobase Million.
4. Discussion
Pain is a subjective and complex sensory experience and evaluation of pain is rather difficult.
Among several methods for pain assessment [28], we used VAS since it is a clinical routine,
well accepted in scientific pain literature and it influences functional scores [29]. Patients with contrast
pain phenotypes were matched for gender (females), smoking status (non-smokers) and ethnic origin
(Europeans) which can confound experiencing the pain [6]. Additionally, patient groups with contrast
pain phenotypes did not differ significantly in age (70.6 ± 6.5 vs. 71.0 ± 6.0 in high vs. low pain
group), Body Mass Index (BMI) (31.1 ± 8.5 vs. 29.0 ± 5.1 in high vs. low pain group) or the extent of
joint damage (3 and 4 in Kellgren and Lawrence grade system). The use of analgesics could decrease
pain in the low pain group patients 021 and 022, but appeared inefficient in controlling the pain in the
high pain group patients 016, 018, 019.
We uncovered a signature of genes that are differentially expressed in the synovial tissues from
knees of OA patients with contrast pain phenotypes. The synovial inflammatory mediators that are
known to induce and/or respond to pain [12] were not enriched in the transcriptome profiles in
synovial tissues from patients with high compared to patients with low knee pain. The deconvolution
analysis of RNA-seq data showed no differences in the composition of immune cells or synovial
fibroblasts between patients. Instead, the three top differentially expressed genes in patients with high
pain are neuronal proteins. Two of them, specifically SDIM1 and CPE, are known for their roles in
cellular responses to stress. This suggests a potential molecular connection between chronic pain and
stress, as also recently demonstrated by Descalzi et al. [30].
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SDIM1 is involved in cellular response to stress and inhibition of cell death [31]. In NT2 neurons
SDIM1 exhibits a bi-phasic response to cell death-inducing injuries; initial down-regulation of SDIM1
is followed by an up-regulation in surviving cells [31]. Overexpression of SDIM1 improves survival
of neuro-progenitor cells after injury, substantiating the pro-survival effects of SDIM1 under stress
conditions [31]. We show an increased expression of SDIM1 in knee synovial tissues from OA patients
with high pain. Our data suggest that acting as a stressor, the chronic pain might increase the expression
of SDIM1 in the synovial microenvironment of OA knees to activate its protective functions.
Besides SDIM1, CPE can steer cellular responses to stress and we show that also CPE is
significantly up-regulated in the synovium of OA patients with high pain. CPE acts as a trophic
factor and promotes neuronal survival upon various stressors via increasing anti-apoptotic protein
BCL-2 Bcl-2 in a MEK/ERK and/or PI3-K/AKT-dependent manner [32]. Stress-driven increase of CPE
in brain has pro-survival effects in neurons [32]. Considering the sensitivity of CPE in responding to
different stressors, pain as a stressor might induce CPE expression in OA knees. CPE acts through a
similar molecular mechanism like brain derived neurotrophic factor (BDNF) [33] which is expressed in
knee synovium of OA patients [13], its expression however does not differ between OA patients with
contrast pain phenotypes. This suggests that CPE and BDNF may not function together to promote
cell survival in painful OA joints; a similar scenario proposed for hippocampal neurons [32]. Instead,
we show increased expression of IGF1, which is known to have neuroprotective and pro-survival
effects by activating ERK and Akt [34].
Collectively, these results suggest that the cell protective functions of SDIM1 and CPE might
be needed within the stress microenvironment of the OA synovium in patients with high pain.
CPE and SDIM1 appear striking molecular candidates for future studies due to its potential joint
protective effects.
OTOF was the second of the top three up-regulated genes in the synovium of OA patients with
high pain. OTOF is a transmembrane protein required for calcium-dependent synaptic exocytosis in
cochlear sensory cells [35] and mutations in OTOF cause deafness [35]. Besides, OTOF can modulate
the GABAergic activity in the GAD65-dependent manner in neuronal and non-neuronal cells [36].
Future studies might reveal whether OTOF can change the secretion of GABA in the OA synovium in
response to pain, thereby modulating the pain transmission.
In the gene networks enrichment analysis using GO terms and Reactome pathways, the networks
that include SDIM1 and OTOF did not appear enriched, possibly due to a rather limited published data
on the function of these genes. Meanwhile, CPE was linked to the anatomical structure morphogenesis.
Several other up-regulated genes in the synovium of OA patients with high pain did not appear in
enriched pathways and the knowledge about most of these genes is rather limited. Nevertheless, some of
these genes participate in nervous system development (CLSTN2, TUBB2B) [37,38], inflammation
including arthritis (AOC3) [39] and stress-induced responses (C10orf10) [40], making them promising
molecular candidates in OA-driven pain.
On the other hand, the neurotrophic tyrosine kinase receptor type 2 (NTRK2), also known as
TrkB was present in every enriched GO term and in both enriched Reactome pathways. This might
suggest that NTRK2 is one of the key drivers, involved in the pain-related transcriptional changes in
the OA synovium. The expression of the neurotrophic factors that function via TrkB including BDNF,
nerve growth factor (NGF), was not altered in OA patients with high knee pain. This suggests that
other molecular candidates might function via TrkB to activate downstream signaling pathways in the
synovium of painful OA joint.
To date no studies have explored the global alterations in the synovial noncoding RNA expression
in relation to OA joint pain. We identified two differentially expressed lncRNAs and 35 differentially
expressed miRNAs in the synovium of OA patients with contrast pain phenotypes, but the differences
in the miRNA expression were not significant when correcting for FDR. In all this suggests that
pain-related transcriptional changes primarily affect the protein coding transcriptome. Pain-associated
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changes in miRNAs in OA appear less frequent or smaller, thus larger sample sizes might be required
for miRNA studies.
The two identified lncRNAs (RN7SL3 and RP11-195E2.1), which were strongly down-regulated
in OA patients with high knee pain, have largely unknown function. In contrast, miR-146a-3p,
the top differentially expressed miRNA in the synovium of OA patient with contrast pain phenotypes,
has already been linked to the pain-related pathophysiology of knee OA [41]. MiR-146a-3p,
which regulates the cell repair responses to tissue damage. It was also shown to be up-regulated in
the cartilage and synovium of OA patients compared with healthy controls, which directly links this
miRNA to OA pathogenesis [41]. We show that miR-146a-3p is down-regulated in the synovium of
OA patients with high pain. This is in line with the observed down-regulation of miR-146a-3p in
peripheral and central neurons in an animal model of OA-pain [41], making miR-146a-3p a prominent
molecular candidate in pain-related pathology in OA.
5. Conclusions
In summary, the molecular dynamics in the synovium of painful OA joints indicate that the
synovium is an important tissue to investigate in the discovery of novel therapeutics to decrease
OA joint pain. The increased expression of stress-inducible molecules with protective roles in cell
survival emerges as a common theme in OA patients with high intensity knee pain. Future studies of
stress-induced protective mechanisms should further deepen the understanding of joint pain in OA.
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